Wang Jinshou
参与了投票
上周美国各州失业救济金的申请下降至 这是自1969年以来的最低水平,说明了根据季节性影响调整原始数据的困难。
最初的失业救济申请总数 184,000 在结束的一周内 12月4日,比上期下降了43,000人,劳工部周四的数据显示。彭博社对经济学家的调查的中位数估计为22万份申请。
最初的失业救济申请总数 184,000 在结束的一周内 12月4日,比上期下降了43,000人,劳工部周四的数据显示。彭博社对经济学家的调查的中位数估计为22万份申请。
已翻译
218
26
Wang Jinshou
留下了心情
Like the vaccines from Moderna $Moderna (MRNA.US)$ and Pfizer-BioNTech $辉瑞 (PFE.US)$ , $诺瓦瓦克斯医药 (NVAX.US)$ Novavax's focuses on the spike protein. And that is why the efficacy levels of these vaccines are so high. So, theoretically, if there are many mutations in the spike protein, the original COVID-19 vaccines won't be as effective.
Nonetheless, Novavax is confident that it will find a vaccine candidate for this new threat. The biotech is now testing its original vaccine, CoV2373, against the omicron variant to see what kind of protections vaccinated people might expect. The company says it will have lab data on that question in a matter of weeks.
Simultaneously, Novavax has initiated development of an omicron-specific construct of its spike protein antigen. First steps are underway, and the company says it will start manufacturing the antigen in January.
Because it's not an mRNA drug but a protein-based vaccine, many experts believe the Novavax vaccine is an ideal booster shot. In a recent article in Nature, the authors concluded that the protein vaccines have a superior safety profile to the mRNA vaccines.
Of course, most of Novavax's COVID-19 shots will be used to vaccinate people abroad. Nonetheless, the U.S. has already acquired 100 million doses of its vaccine candidate. So if there's a demand for boosters next year, Novavax investors should do really well.
Article excerpted from The Motley Fool.
Nonetheless, Novavax is confident that it will find a vaccine candidate for this new threat. The biotech is now testing its original vaccine, CoV2373, against the omicron variant to see what kind of protections vaccinated people might expect. The company says it will have lab data on that question in a matter of weeks.
Simultaneously, Novavax has initiated development of an omicron-specific construct of its spike protein antigen. First steps are underway, and the company says it will start manufacturing the antigen in January.
Because it's not an mRNA drug but a protein-based vaccine, many experts believe the Novavax vaccine is an ideal booster shot. In a recent article in Nature, the authors concluded that the protein vaccines have a superior safety profile to the mRNA vaccines.
Of course, most of Novavax's COVID-19 shots will be used to vaccinate people abroad. Nonetheless, the U.S. has already acquired 100 million doses of its vaccine candidate. So if there's a demand for boosters next year, Novavax investors should do really well.
Article excerpted from The Motley Fool.
1
Wang Jinshou
赞了
3
Wang Jinshou
参与了投票
每日民意调查
自从美国对环境问题给予更多关注以来,汽车制造商正在向其产品阵容中增加更多的电动汽车。拜登政府还计划公布新的汽车排放规则。根据 $通用汽车 (GM.US)$ 在季度报告中,他们计划将对电动和自动驾驶汽车的投资从270亿美元增加到350亿美元。
汽车制造商包括, $福特汽车 (F.US)$ , $Stellantis NV (STLA.US)$
自从美国对环境问题给予更多关注以来,汽车制造商正在向其产品阵容中增加更多的电动汽车。拜登政府还计划公布新的汽车排放规则。根据 $通用汽车 (GM.US)$ 在季度报告中,他们计划将对电动和自动驾驶汽车的投资从270亿美元增加到350亿美元。
汽车制造商包括, $福特汽车 (F.US)$ , $Stellantis NV (STLA.US)$
已翻译
12
3
Wang Jinshou
赞了
$Palantir (PLTR.US)$
暂时不用慌,上次解禁了80%的股份才暴跌,今天据说第二次解禁才跌了5%,成交量也不算高。
跌不破20不用跑。 该跑的早跑差不多了,你现在割不怕割在地板上?
跌破20离现在也就5个点左右的损失。要割也得等反弹不是?
暂时不用慌,上次解禁了80%的股份才暴跌,今天据说第二次解禁才跌了5%,成交量也不算高。
跌不破20不用跑。 该跑的早跑差不多了,你现在割不怕割在地板上?
跌破20离现在也就5个点左右的损失。要割也得等反弹不是?
12
3